Mephedrone: Public health risk, mechanisms of action, and behavioral effects

European Journal of Pharmacology

Volumn 714, Issue 1-3, 2013, Pages 32-40

  Dybdal Hargreaves, Nicholas F ^a   Holder, Nicholas D ^a   Ottoson, Paige E ^a   Sweeney, Melanie D ^a   Williams, Tyisha ^a  

^a TRINITY UNIVERSITY   (United States)

Author keywords

Amphetamines; Bath salts; Mechanism; Mephedrone; Synthetic cathinone

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4' METHYLMETHCATHINONE; 4' METHYLMETHCATHINONE DERIVATIVE; AMPHETAMINE DERIVATIVE; COCAINE; DESIGNER DRUG; DOPAMINE; DRUG METABOLITE; METHAMPHETAMINE; METHCATHINONE; METHYLONE; SEROTONIN; UNCLASSIFIED DRUG;

DECISION MAKING; DOPAMINERGIC ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG RESEARCH; DRUG STRUCTURE; HEALTH HAZARD; HUMAN; LEGAL ASPECT; NONHUMAN; POLICY; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; SEROTONINERGIC SYSTEM;

AMPHETAMINES; BATH SALTS; MECHANISM; MEPHEDRONE; SYNTHETIC CATHINONE;

ANIMALS; BEHAVIOR; HUMANS; METHAMPHETAMINE; PUBLIC HEALTH; RISK;

EID: 84879496082     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.05.024     Document Type: Review

References (106)

1. Angoa-Peréz, M., Kane, M.J., Francescutti, D.M., Sykes, K.E., Shah, M.M., Mohammed, A.M., Thomas, D.M., Kuhn, D.M., 2012. Mephedrone, an abused psychoactive component of 'bath salts' and methamphetamine congener, does not cause neurotoxicity to dopamine nerve endings of the striatum. J. Neurochem. 120, 1097-1107.
2. Badon, LA, Hicks, A., Lord, K., Ogden, B.A., Meleg-Smith, S., Varner, K.J., 2002. Changes in cardiovascular responsiveness and cardiotoxicity elicited during binge administration of ecstasy. J. Pharmacol. Exp. Ther. 302, 898-901.
3. Baron, M., Elie, M., Elie, L, 2011. An analysis of legal highs - do they contain what it says on the tin? Drug Test. Anal. 3, 576-581.
4. Baumann, M.H., Rothmann, R.B., 2009. Neural and cardiac toxicities associated with 3,4-methylenedioxymethamphetamine (MDMA). Int Rev. Neurobiol. 88, 257-296.
5. Baumann, M.H., Ayestas Jr., M.A., Partilla, J.S., Sink, J.R., Shulgin, A.T., Daley, P.F., Brandt, S.D., Rothman, R.B., Ruoho, A.E., Cozzi, N.V., 2011. The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 37, 1192-1203.
6. Baumann, M.H., Partilla, J.S., Lehner, K.R., 2013a. Psychoactive "bath salts,": not so soothing. Eur. J. Pharmacol. 698, 1-5.
7. Baumann, M.H., Partilla, J.S., Lehner, K.R., Thorndike, E.B., Hoffman, A.F., Holy, M., Rothman, R.B., Goldberg, S.R., Lupica, CR., Sitte, H.H., Brandt, S.D., Tella, S.R., Cozzi, N.V., Schindler, C.W., 2013b. Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive bath salts' products. Neuropsychopharmacology 38, 552-562.
8. Bentur, Y., Bloom-Krasik, A., Raikhlin-Eisenkraft, B., 2008. Illicit cathinone ("Hagi-gat,") poisoning. Clin. Toxicol. (Phila) 46, 206-210.
9. Bijlsma, L, Sancho, J.V., Hernandez, F., Niessen, W.M.A., 2011. Fragmentation pathways of drugs of abuse and their metabolites based on QTOF MS/MS and MSE accurate-mass spectra. J. Mass Spectrom. 46, 865-875.
10. Bogen, I.L., Haug, K.H., Myhre, O., Fonnum, F., 2003. Short-and long-term effects of MDMA ("ecstasy,") on synaptosomal and vesicular uptake of neurotransmitters in vitro and ex vivo. Neurochem. Int 43, 393-400. (Pubitemid 36561293)
11. Brandt, S.D., Sumnall, H.R., Measham, F., Cole, J., 2010. Analyses of second generation 'legal highs' in the UK: initial findings. Drug Test. Anal 2, 377-381.
12. Brunt, T.M., Poortman, A., Niesink, R.J.M., van den Vrink, W., 2011. Instability of the ecstasy market and a new kid on the block: mephedrone. J. Psychopharmacol. 25, 1543-1547.
13. Cameron, K.N., Kolanos, R., Solis, E., Glennon, RA, De Felice, L.J., 2012. Bath salts components mephedrone and methylenedioxypyrovalerone (MDPV) act syner-gistically at the human dopamine transporter. Br. J. Pharmacol.
14. Cameron, K., Kolanos, R., Verkariya, R., De Felice, L, Glennon, R.A., 2013. Mephedrone and methylenedioxypyrovalerone (MDPV), major constituents of "bath salts," produce opposite effects at the human dopamine transporter. Psycho-pharmacology. (ePub).
15. Carhart-Harris, R.L, King, LA., Nutt, D.J., 2011. A web-based survey on mephedrone. Drug Alcohol Depend. 118, 19-22.
16. Carroll, F.I., Lewin, A.H., Mascarella, S.W., Seltzman, H.H., Reddy, P.A., 2012. Designer drugs: a medicinal chemistry perspective. Ann. N.Y. Acad. Sci. 1248, 18-38.
17. Ciechomska, M., Wozniakiewicz, M., Wietecha-Posluszny, R., 2012. Activity and biotransformation of three synthetic "legal highs,": mephedrone, methylone, and 3,4-methylenodioxypyrovalerone. Prob. Forensic Sci. 89, 71-85.
18. Colzato, L.S., Ruiz, M.J., Wildenberg, W.P.M., Hommel, B., 2012. Khat use is associated with increased response conflict in humans. Hum. Psychopharmacol 27, 315-321.
19. Cone, E.J., Huestis, M.A., 2007. Interpretation of oral fluid tests for drugs of abuse. Ann. N.Y. Acad. Sci., 1098.
20. Coppola, M., Mondola, R., 2012. Synthetic cathinones: chemistry, pharmacology and toxicology of a new class of designer drugs of abuse marketed as "bath salts" or "plant food,". Toxicol. Lett. 211, 144-149.
21. Cornish, J.L., Hunt, G.E., Robins, L., McGregor, I.S., 2012. Regional c-Fos and FosB/AFosB expression associated with chronic methamphetamine self-administration and methamphetamine-seeking behavior in rats. Neuroscience 206, 100-114.
22. Cozzi, N.V., Brandt, S.D., Daley, P.F., Partilla, J.S., Rothman, R.B., Tulzer, A., Sitte, H.H., Baumann, M.H., 2013. Pharmacological examination of trifluoromethyl ring-substituted methcathinone analogs. Eur. J. Pharmacol. 699, 180-187.
23. Cozzi, N.V., Foley, K.F., 2003. Methcathinone is a substrate for the serotonin uptake transporter. Pharmacol. Toxicol. 93, 219-225. (Pubitemid 37521958)
24. Cozzi, N.V., Sievert, M.K., Shulgin, A.T., Jacob III, P., Ruoho, A.E., 1999. Inhibition of plasma membrane monoamine transporters by b-ketoamphetamines. Eur. J. Pharmacol. 381, 63-69. (Pubitemid 29488590)
25. Cunningham, K.A., Callahan, P.M., 1991. Monoamine reuptake inhibitors enhance the discriminative state induced by cocaine in the rat. Psychopharmacology 104, 177-180.
26. Dargan, P.I., Sedefov, R., Gallegos, A., Wood, D.M., 2011. The pharmacology and toxicology of the synthetic cathinone mephedrone (4-methylmethcathinone). Drug Test. Anal. 3, 454-464.
27. Davidson, C, Gow, A.J., Lee, T.H., Ellinwood, E.H., 2001. Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res. Rev. 36, 1-22. (Pubitemid 32763126)
28. Dawson, P., Moffatt, J.D., 2012. Cardiovascular toxicity of novel psychoactive drugs: lessons from the past. Prog. Neuropsychopharmacol. Biol. Psychiatry 39, 244-252.
29. den Hollander, B., Rozov, S., Linden, A.M., Uusi-Oukari, M., Ojanperä, I., Korpi, E.R., 2012. Long-term cognitive and neurochemical effects of "bath salt," designer drugs methylone and mephedrone. Pharmacol. Biochem. Behav. 103, 501-509.
30. Dickson, A.J., Vorce, S.P., Levine, B., Past, M.R., 2010. Multiple-drug toxicity caused by the coadministration of 4-methylmethcathinone (mephedrone) and heroin. J. Anal. Toxicol. 34, 162-168.
31. Falkowski, C, 2011. Illegal drug impersonators: the synthetic drug abuse boom. Minn. Med. 94, 52.
32. Fleckenstein, A.E., Volz, T.J., Riddle, E.L., Gibb, J.W., Hanson, G.R., 2007. New insights into the mechanism of action of amphetamines. Annu. Rev. Pharmacol. Toxicol. 47, 681-698.
33. Freeman, T.P., Morgan, C.J., Vaughn-Jones, J., Hussain, N., Karimi, K., Curran, H.V., 2012. Cognitive and subjective effects of mephedrone and factors influencing use of a 'new legal high'. Addiction 107, 792-800.
34. Garrett, G., Sweeney, M., 2010. The Serotonin Syndrome as a Result of Mephedrone Toxicity. B.M.J. Case Reports, bcr0420102925.
35. Green, A.R., O'Shea, E., Colado, M.I., 2004a. A review of the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic response. Eur. J. Pharmacol 500, 3-13. (Pubitemid 39303992)
36. Green, A.R., Sanchez, V., O'Shea, E., Saadat, K.S., Elliott, J.M., Colado, M.I., 2004b. Effect of ambient temperature and a prior neurotoxic dose of 3,4-methylene-dioxymethamphetamine (MDMA) on the hyperthermic response of rats to a single or repeated ('binge' ingestion) low dose of MDMA. Psychopharmacology 173, 264-269. (Pubitemid 38703799)
37. Hadlock, G.C., Webb, K.M., McFadden, L.M., Chu, P.W., Ellis, J.D., Allen, S.C., Andrenyak, D.M., Vieira-Brock, P.L., German, C.L., Conrad, K.M., and Hoonakker., A. J., Gibb, J.W., Wilkins, D.G., Hanson, G.R., Fleckenstein, A.E., 2011. 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse. J. Pharmacol. Exp. Ther. 339, 530-536.
38. Haggin, P., 2012, July 10. Obama Signs Federal Ban on 'Bath Salt' Drugs. TIME. Retrieved from (http:/newsfeed.time.com/2012/07/10/obama-signs-federal- ban-on-bath-salt-drugs).
39. James, D., Adams, R.D., Spears, R., Cooper, G., Lupton, D.J., Thompson, J.P., Thomas, S. H.L, 2011. Clinical characteristics of mephedrone toxicity reported to the UK National Poisons Information Service. Emerg. Med. J. 28, 686-689.
40. Jatlow, P., 1988. Cocaine: analysis, pharmacokinetics, and metabolic disposition. Yale J. Biol. Med. 61, 105.
41. Jerry, J., Collins, G., Streem, D., 2012. Synthetic legal intoxicating drugs: the emerging 'incense' and 'bath salt' phenomenon. Cleve. Clin. J. Med. 79, 258-264.
42. Johnson, M.P., Conarty, P.F., Nichols, D.E., 1991. H Monoamine releasing and uptake inhibition properties of 3,4-methylenedioxymethamphetamine and p-chlor-oamphetamine analogues. Eur. J. Pharmacol. 200, 9-16.
43. Jones, S.R., Gainetdinov, R.R., Wightman, R.M., Caron, M.G., 1998. Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J. Neurosci. 18, 1979-1986. (Pubitemid 28141404)
44. Kamata, H.T., Shima, N., Zaiksu, K., Kamata, T., Nishikawa, M., Katagi, M., Miki, A., Tsuchihashi, H., 2007. Simultaneous analysis of new designer drug, methylone, and its metabolites in urine by gas chromatography mass spectrometry and liquid chromatography - electrospray ionization mass spectrometry. Jpn. J. Forensic Sci. Technol 12, 97-106.
45. Karila, L., Reynaud, M., 2011. GHB and synthetic cathinones - clinical effects and potential consequences. Drug Test. Anal 3, 552-559.
46. Kehr, J., Ichinose, F., Yoshitake, S., Goiny, M., Sievertsson, T., Nyberg, F., Yoshitake, T, 2011. Mephedrone, compared to MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and serotonin levels in nucleus accumbens of awake rats. Br. J. Pharmacol. 164, 1949-1958.
47. Khreit, O.I., Grant, M.H., Zhang, T., Henderson, C, Watson, D.G., Sutcliffe, O.B., 2012. Elucidation of the Phase I and Phase II metabolic pathways of (±)-4'-methylmethcathinone (4-MMC) and (±)-4'- (trifluoromethyl) methcathinone (4-TFMMC) in rat liver hepatocytes using LC-MS and LC-MS. J. Pharmaceut. Biomed. Anal.
48. Kittler, K., Lau, T., Schloss, P., 2010. Antagonists and substrates differentially regulate serotonin transporter cell surface expression in serotonergic neurons. Eur. J. Pharmacol. 629, 63-67.
49. Kivell, B., Day, D., Bosch, P., Schenk, S., Miller, J., 2010. MDMA causes a redistribution of serotonin transporter from the cell surface to the intracellular compartment by a mechanism independent of phospho-p38-mitogen activated protein kinase activation. Neuroscience 168, 82-95.
50. Kokoshka, J.M., Vaughan, R.A., Hanson, G.R., Fleckenstein, A.E., 1998. Nature of methamphetamine-induced rapid and reversible changes in dopamine transporters. Eur. J. Pharmacol. 361, 269-275. (Pubitemid 29000982)
51. Koob, G.F., Bloom, F.E., 1988. Cellular and molecular mechanisms of drug dependence. Science 242, 715-723.
52. Li, L., Everhart, T., Jacob III, P., Jones, R., Mendelson, J., 2010. Stereoselectivity in the human metabolism of methamphetamine. Br. J. Clin. Pharmacol. 69, 187-192.
53. Lisek, R., Xu, W, Yuvasheva, E., Chiu, Y, Reitz, A.B., Liu-Chen, L., Rawls, S.M., 2012. Mephedrone ('bath salt') elicits conditioned place preference and dopamine-sensitive motor activation. Drug Alcohol Depen 126, 257-262.
54. Loeffler, G., Penn, A., Ledden, B., 2012. Bath salt-induced agitated paranoia: a case series. J. Stud. Alcohol Drugs 73, 706.
55. Lopez-Arnua, R., Martinez-Clemente, J., Pubill, D., Escubedo, E., Camarasa, J., 2012. Comparative neuropharmacology of three psychostimulant cathinone derivatives: butylone, mephedrone and methylone. Br. J. Pharmacol. 167, 407-420.
56. Marusich, JA, Grant, K.R., Blough, B.E., Wiley, J.E., 2012. Effects of synthetic cathinones contained in "bath salts," on motor behavior and a functional observational battery in mice. Neurotoxicology 33, 1303-1315.
57. Martínez-Clementine, J., Escubedo, E., Pubill, D., Camarasa, J., 2012. Interaction of mephedrone with dopamine and serotonin targets in rats. Eur. Neuropsycho-pharmacol. 22, 231-236.
58. Mas-Morey, P., Visser, M.H.M., Winkelmolen, L., Touw, D.J., 2012. Clinical toxicology and management of intoxications with synthetic cathinones ("bath salts,"). J. Pharm. Pract. (Epub).
59. McCann, U.D., Wong, D.F., Yokoi, F., Villemagne, V., Dannals, R.F., Ricuarte, G.A., 1998. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. J. Neurosci. 18, 8417-8422. (Pubitemid 28465016)
60. McElrath, K., O'Neill, C, 2011. Experiences with mephedrone pre-and post-legislative controls: perceptions of safety and sources of supply. Int. J. Drug Policy 22, 120-127.
61. McGaw, C, Kankam, O., 2010. The coingestion of alcohol and mephedreon - an emerging cause of acute medical admissions in young adults and a potential cause of tachyarrhythmias. West London Med. J 2, 9-13.
62. Meng, H., Cao, J., Kang, J., Ying, X., Ji, J., Reynolds, W., Rampe, W, 2012. Mephedrone, a new designer drug of abuse, produces acute hemodynamic effects in the rat. Toxicol. Lett. 208, 62-68.
63. Meyer, M., Maurer, H., 2010. Metabolism of designer drugs of abuse: an updated review. Curr. Drug Metab. 11, 468-482.
64. Meyer, M.R., Peters, F.T., Maurer, H.H., 2008. The role of human hepatic cytochrome P450 isozymes in the metabolism of racemic 3,4- methylenedioxymethamphe-tamine and its enantiomers. Drug Metab. Dispos. 36, 2345-2354.
65. Meyer, M.R., Wilhelm, J., Peters, F.T., Maurer, H.H., 2010. Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography-mass spectrometry. Anal. Bioanal. Chem. 397, 1225-1233.
66. Miyazawa, M., Kojima, T., Nakaji, S., 2011. Behavioral and rewarding effects of methylone, an analog of MDMA in mice. Hirosaki Igaku 62, 56-71.
67. Motbey, C.P., Hunt, G.E., Bowen, M.T., Artiss, S., McGregor, I.S., 2011. Mephedrone (4-methylmethcathinone, 'meow'): acute behavioral effects and distribution of Fos expression in adolescent rats. Addict. Biol. 17, 409-422.
68. Motbey, C.P., Karanges, E., Li, K.M., Wilkinson, S., Winstock, A.R., Ramsay, J., Hicks, C, Kendig, M.D., Wyatt, N., Callaghan, P.D., McGregor, I.A., 2012. Mephedrone in adolescent rats: residual memory impairment and acute but not lasting 5-HT depletion. PLoS One 7, e45473.
69. Nagai, F., Nonaka, R., Satoh Hishashi Kamimura, K., 2007. The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur. J. Pharmacol 559, 132-137. (Pubitemid 46295399)
70. National Highway Traffic Safety Administration, 2004. Drugs and Human Performance Fact Sheet. (Report No. DOT HS 809 725). Retrieved from: (www.nhtsa.gov/people/injury/research/job185drugs/drugs-web.pdf).
71. National Institute on Drug Abuse, 2011. Epidemiologic trends in drug abuse. In: Proceedings of the Community Epidemiology Work Group. Retrieved from: (www.drugabuse.gov/sites/default/%20files/cewgjune2011-vol-ii-508.pdf).
72. North, A., Swant, J., Salvatore, M.F., Gamble-George, J., Prins, P., Butler, B., Mittal, M. K., Heltsley, R., Clark, J.T., Khosbouie, J., 2013. Chronic methamphetamine exposure produces a delayed, long-lasting memory deficit. Synapse 67, 245-257.
73. Nyberg, F., 2012. Cognitive impairments in drug addicts, brain damage. In: Gonzalez-Quevedo, A. (Ed.), Bridging Between Basic Research and Clinics. InTech.
74. Olives, T.D., Orozco, B.S., Stellpflug, S.J., 2012. Bath salts: the ivory wave of trouble. West. J. Emerg. Med 13, 58.
75. O'Neil, M.L, Kuczenski, R., Segal, D.S., Cho, A.K., Lacan, G., Melega, W.P., 2006. Escalating dose pretreatment induces pharmacodynamic and not pharmacokinetic tolerance to a subsequent high-dose methamphetamine binge. Synapse 60, 465-473. (Pubitemid 44380158)
76. Pedersen, A.J., Petersen, T.H., Linnet, K., 2013. In vitro metabolism and kinetic studies on methylone. Drug Metab. Dispos. (ePub).
77. Psychonaut WebMapping Research Group, 2009. Mephedrone Report: Institute of Psychiatry. King's College London, London UK
78. Ramoz, L., Lodi, S., Bhatt, P., Reitz, A.B., Tallarida, C, Tallarida, R.J., Raffa, R.B., Rawls, S.M., 2012. Mephedrone ("bath salt,") pharmacology: insights from invertebrates. Neuroscience 208, 79-84.
79. Robinson, J.E., Agoglia, A.E., Fish, E.W, Krouse, M.C., Malanga, C.J., 2012. Mephedrone (4-methylmathcathinone and intracranial self-stimulation in C57BL/6 J mice: comparison to cocaine. Behav. Brain Res. 234, 76-81.
80. Rothman, R.B., Baumann, M.H., Dersch, CM., Romero, D.V., Rice, K.C., Carroll, F.I., Partilla, J.S., 2001. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39, 32-41.
81. Saunders, C.C., Ferrer, J.V., Shi, L., Chen, J., Merrill, G., 2000. Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism. Proc. Nat. Acad. Sci. U.S.A 97, 6850-6855. (Pubitemid 30412803)
82. Schep, L.J., Slaughter, R.J., Beasley, D.M., 2010. The clinical toxicology of metamfetamine. Clin. Toxicol. (Phila,) 48, 675-694.
83. Schifano, F., Albanese, A., Fergus, S., Stair, J.L, DeLuca, P., Corazza, O., 2011. Mephedrone (4-methylmethcathinone;'meow meow'): chemical, pharmacological and clinical issues. Psychopharmacology 214, 593-602.
84. Schwendt, M., Rocha, A., See, R.E., Pacchioni, A.M., McGinty, J.F., Kalivas, P.W, 2009. Extended methamphetamine self-administration in rats results in a selective reduction of dopamine transporter levels in the prefrontal cortex and dorsal striatum not accumpanied by marked monoaminergic depletion. J. Pharmacol. Exper. Ther 331, 555-562.
85. Shima, N., Katagi, M., Tsuchihashi, H., 2009. Direct analysis of conjugate metabolites of methamphetamine, 3,4-methylenedioxymethamphetamine, and their designer drugs in biological fluids. J. Health Sci. 55, 495-502.
86. Shortall, S.E., Green, A.R., Swift, K.M., Fone, K.C.F., King, M.V., 2013. Differential effects of cathinone compounds and MDMA on body temperature in the rat, and pharmacological characterization of mephedrone-induced hypothermia. Br. J. Pharmacol. 168, 966-977.
87. Shortall, S.E., Macerola, A.E., Swaby, R.T.R., Jayson, R., Korsah, C, Pillidge, K.E., Wigmore, P.E., 2012. Behavioural and neurochemical comparison of chronic intermittent cathinone, mephedrone and MDMA administration to the rat. Eur. Neuropsychopharmacol. 12, 269.
88. Simmler, L.D., Buser, TA, Donzelli, M., Schramm, Y., Dieu, L.H., Huwyler, J., Chaboz, S., Hoener, M.C., Liechti, M.E., 2013. Pharmacological characterization of designer cathinones in vitro. Br. J. Pharmacol. 168, 458-470.
89. Sindicich, N., Burns, L, 2012. Ecstasy returns and the emerging class of drugs, EDRS Drug Trends Bulletin, October. National Drug and Alcohol Research Centre, University of New South Wales, Sydney p. 2012.
90. Sogawa, C, Sogawa, N., Ohyama, K., Kikura-Hanajiri, R., Goda, Y., Sora, I., Kitayama, S., 2011. Methylone and monoamine transporters: correlation with toxicity. Curr. Neuropharmacol. 9, 58-62.
91. Steele, T.D., Nichols, D.E., Yim, G.K., 1987. Stereochemical effects of 3,4-methylene-dioxymethamphetamine MDMA and related amphetamine derivatives on inhibition of uptake of H monoamines into synaptosomes from different regions of rat brain. Biochem. Pharmacol 36, 2297-2303. (Pubitemid 17097404)
92. Thanacoody, R., 2012. Serotonin syndrome. Medicine 40, 63-64.
93. Thomas, D.M., Francescutti-Verbeem, D.M., Kuhn, D.M., 2009. Increases in cytoplasmic dopamine compromise the normal resistance of the nucleus accum-bens to methamphetamine neurotoxicity. J. Neurochem. 109, 1745-1755.
94. Thomsen, M., Hall, F.S., Uhl, G.R., Caine, S.B., 2009. Dramatically decreased cocaine self-administration in dopamine but not serotonin transporter knock-out mice. J. Neurosci. 29, 1087-1092.
95. Valente, M.J., Carcalho, F., Bastos, M.L., Carvalho, M., Guedes de Pinho, P., 2010. Development and validation of a gas chromatography/ion trap-mass spectrometry method for simultaneous quantification of cocaine and its metabolites benzoylechonine and norcocaine: application to the study of cocaine metabolism in human primary cultured renal cells. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci 878, 3083-3088.
96. Van Hout, M.C., Brennan, R., 2011. "Bump and grind,": an exploratory study of mephedrone users; perceptions of sexuality and sexual risk. Drugs Alcohol Today 11, 93-103.
97. Van Hout, M.C., Bingham, T., 2012. A Costly Turn On: patterns of use and perceived consequences of mephedrone based head shop products amongst Irish injectors. Int. J. Drug Policy 23, 188-197.
98. Vardakou, I., Pistos, C, Spiliopoulou, C, 2011. Drugs for youth via Internet and the example of mephedrone. Toxicol. Lett. 201, 191-195.
99. Varner, KJ, Daigle, K. Weed, P.F., Lewis, PB., Mahne, S.E, Sankaranarayanan, A., Winsauer, P.J., 2012. Comparison of the behavioral and cardiovascular effects of mephedrone with other drugs of abuse in rats. Psychopharmacology (Berl) (Epub).
100. Volkow, N.D., Chang, L., Wang, G.J., Fowler, J.S., Franceschi, D., Sedler, M., Gatley, S.J., Miller, E, Hitzemann, R., Ding, Y.S., Logan, J., 2001. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J. Neurosci. 21, 9414-9418. (Pubitemid 33096884)
101. Vollenweider, F.X., Gamma, A., Liechti, M., Huber, T, 1998. Psychological and cardiovascular effects and short-term sequelae of MDMA ("ecstasy, ") in MDMA-naïve healthy volunteers. Neuropsychopharmacology 19, 241-251. (Pubitemid 28491334)
102. Winstock, A.R., Mitcheson, L.R., Deluca, P., Davey, Z., Corazza, O., Schifano, F., 2010. Mephedrone, new kid for the chop? Addiction 106, 154-161.
103. Winstock, A., Mitcheson, L., Ramsey, J., Davies, S., Puchnarewicz, M., Marsden, J., 2011. Mephedrone: use, subjective effects and health risks. Addiction 106, 1991-1996.
104. Wood, D.M., Dargan, P.I., 2012. Mephedrone (4-methylmethcathinone): what is new in our understanding of its use and toxicity. Prog. Neuropsychopharmacol. Biol. Psychiatry 39, 227-233.
105. Wood, D.M., Davies, S., Greene, S.L, Button, J., Holt, D.W., Ramsey, J.R., Dargan, P.L, 2010. Case series of individuals with analytically confirmed acute mephedrone toxicity. Clin. Toxicol. 48, 924-927.
106. Wright, J.M., Angrish, D., Aarde, S.M., Barlow, D.J., Buczynski, M.W, Creehan, K.M, Vandewater, S.A., Parsons, LH., Houseknecht, K.L., Dickerson, T.J., Taffe, M.A., 2012. Effect of ambient temperature on the thermoregulatory and locomotor stimulant effects of 4-methylmethcathinone in Wistar and Sprague-Dawley rats. PLoS One 7, e44652.